Fenwick Represents Sema4 in Combination with CM Life Sciences SPAC and Debut as Publicly Traded AI-driven Genomic & Clinical Data Platform Company

Fenwick represented Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, in the completion of its business combination with CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company (SPAC), sponsored by affiliates of Casdin Capital and Corvex Management.

The resulting combined company, Sema4 Holdings Corp (“Sema4”), commenced trading of its shares of common stock and warrants on the Nasdaq Global Select Market under the ticker symbols “SMFR” and “SMFRW” on July 23, 2021. The merger was approved by the stockholders of CM Life Sciences on July 21, 2021. More information can be obtained from the company’s announcement.

Fenwick previously represented Sema4 in its definitive business combination agreement with CM Life Sciences in February 2021, its $121 million Series C financing in July 2020, and its $127 million Series B financing in August 2019. 

The Fenwick transaction team included corporate partners Ethan Skerry, Robert Freedman, Per Chilstrom and David Michaels, associates Victoria Lupu, Darius Alam, Steven Jean, Kristen Nicol, Cedrick Dalluge, Sarah Hill and Jennifer Wu and law clerk Riddhi Adhikari; executive compensation and employee benefits partner Matthew Cantor and associates Corinne Nhaissi and Cynthia Yuan; technology transactions partner Jake Handy and associates Jennifer Yoon and Jefferson Lin and law clerk Zach Harned; antitrust and trade regulation partner Mark Ostrau; privacy and cybersecurity counsel Helen Christakos; and tax partner David Forst.